The trial enrolled 754 patients across study sites in seven countries managed by Interactive Research and Development, Médecins Sans Frontières, and Partners In Health, with help from researchers and clinicians at HMS and Brigham and Women's Hospital and other academic medical centers and research hubs around the world.